一个新的癌症治疗方案ALG.APV-527显示前景良好,第一阶段试验结果积极,使56%的患者受益。 A new cancer treatment, ALG.APV-527, shows promise with positive phase 1 trial results, benefiting 56% of patients.

Aptevo治疗学和鳄鱼生物科学组织报告说,对ALG.APV-527的第一阶段试验取得了积极成果,ALG.APV-527是治疗癌症的一个新的双性特定抗体。 Aptevo Therapeutics and Alligator Bioscience have reported positive results from a phase 1 trial for ALG.APV-527, a new bispecific antibody for cancer treatment. 该药物达到了安全和成效目标,56%的病人患有稳定疾病。 The drug met safety and effectiveness goals, with 56% of patients showing stable disease. 值得注意的是,它没有显示严重的肝毒性,这是类似治疗中常见的副作用。 Notably, it showed no serious liver toxicity, a common side effect in similar treatments. 审判涉及5T4抗原表达的各种固态肿瘤患者。 The trial involved patients with various solid tumors expressing the 5T4 antigen.